No profile data available.
Zai Lab Limited (ZLAB) is a healthcare company in the additional cancer treatment drugs industry, based in Pudong, China, with about 1,784 full-time employees.
It reported revenue of $398.99 million for fiscal year 2024, up 49.6% from fiscal year 2023, and net income of -$257.10 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $116.10 million, up 13.5% from a year before. Its market capitalization was $2.81 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases.
Zai Lab reported $398.99 million in revenue for fiscal year 2024, up 49.6% from $266.72 million in fiscal year 2023. In Q3 2025 revenue was $116.10 million.
$2.81 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Ideaya Biosciences, Inc. (IDYA), Arcus Biosciences, Inc. (RCUS), Enliven Therapeutics, Inc. (ELVN), Hutchmed (China) Limited (HCM).